Analog nicotine composition, liquid preparation, and method of preparation and use thereof

Abstract

The present application relates to the technical field of electronic atomization, in particular to a simulated nicotine composition, a liquid preparation and a preparation method and application thereof. The simulated nicotine composition provided by the present application comprises a first composition and a second composition; the first composition comprises lactamide; and the second composition comprises piperine. The present application selects a specific first composition and a specific second composition as the simulated nicotine composition, and the synergistic effect of the two components can improve the satisfaction of zero-nicotine liquid preparation or low-concentration nicotine liquid preparation, so as to achieve the physiological purpose of the user's addiction.

Description

Technical Field

[0001] This invention relates to the field of electronic atomization technology, specifically to a nicotine-simulating composition, a liquid formulation, its preparation method, and its application. Background Technology

[0002] Electronic atomizing devices mainly consist of a battery, an atomizer, nicotine liquid, and a mouthpiece. The battery provides power to the atomizer, which heats the nicotine liquid and atomizes it into tiny particles, forming an aerosol. Consumers inhale these aerosols through the mouthpiece, thus obtaining an experience similar to smoking. Based on nicotine content, electronic atomizing devices can be divided into nicotine-containing and nicotine-free categories. Nicotine-containing electronic atomizing devices satisfy the smoker's physiological needs through nicotine release, while nicotine-free electronic atomizing devices primarily rely on other ingredients to provide taste and satisfaction. With increasing public awareness of health, many countries have strengthened their regulations on e-cigarettes. Nicotine-containing electronic atomizing devices are limited to a nicotine content of no more than 20mg / g, and many countries are promoting nicotine-free electronic atomizing devices.

[0003] Nicotine is addictive and a primary substance in the formation of nicotine addiction. Therefore, for many smokers, it is crucial that low-nicotine or zero-nicotine products can satisfy their physiological cravings and achieve a high level of satisfaction without posing excessive health risks. Currently, low-nicotine and zero-nicotine products mainly attract consumers with their rich flavors and cool, refreshing sensation. To address the lack of satisfaction, some researchers have tried adding natural alkaloids from traditional Chinese medicine to enhance the product's satisfaction. However, this method can affect the product's aroma and flavor, reducing its overall taste quality, and has limited effect on improving satisfaction. Summary of the Invention

[0004] The purpose of this invention is to overcome the limitations of existing low-concentration nicotine and zero-nicotine products in improving satisfaction, and to provide a nicotine-simulating composition, liquid formulation, preparation method and application thereof.

[0005] To achieve the above objectives, the present invention adopts the following technical solution:

[0006] This invention provides a nicotine-simulating composition, the nicotine-simulating composition comprising a first composition and a second composition;

[0007] The first composition includes lactamide;

[0008] The second composition includes piperine.

[0009] Preferably, the mass ratio of the first composition to the second composition is (1-30):(0.05-0.5).

[0010] Preferably, the first composition further includes magnolol.

[0011] Preferably, the mass ratio of lactamide to magnolol is (1-15):(1-15).

[0012] Preferably, the first composition is lactamide and magnolol, and the second composition is piperine;

[0013] Optionally, the mass ratio of lactamide, magnolol and piperine is (1-15):(1-15):(0.01-0.5).

[0014] The present invention provides a liquid formulation, wherein the raw material components of the liquid formulation include an atomizing solvent and the above-described nicotine-simulated composition.

[0015] Preferably, the mass concentration of the simulated nicotine composition in the liquid formulation is 0.5%-30.5%.

[0016] Preferably, the mass concentration of the first composition in the liquid formulation is 0.5%-30%.

[0017] And / or, the mass concentration of the second composition in the liquid formulation is 0.0005%-0.5%.

[0018] Optionally, the mass concentration of the atomizing solvent in the liquid formulation is 40%-90%.

[0019] Preferably, the atomizing solvent includes at least one of propylene glycol and glycerol.

[0020] Preferably, the atomizing solvent is propylene glycol and glycerol;

[0021] Optionally, the mass ratio of propylene glycol to glycerol is (1-10):(1-10).

[0022] Preferably, the raw material components of the liquid preparation also include flavoring.

[0023] Preferably, the flavoring includes at least one of strawberry flavoring, mint flavoring, and mango flavoring.

[0024] Preferably, the mass ratio of the simulated nicotine composition to the fragrance is (0.05-30.5):(20-400).

[0025] This invention provides a method for preparing the above-described liquid formulation, comprising the following steps:

[0026] The nicotine-simulated composition is obtained by mixing it with an atomizing solvent and then heating and stirring until homogeneous.

[0027] Preferably, the preparation method of the liquid formulation further includes a step of adding flavoring before the heating and stirring step.

[0028] This invention provides an application of the above-described nicotine-simulated composition, the above-described liquid formulation, or the liquid formulation prepared by the above-described preparation method in an atomizing device.

[0029] Preferably, the atomizing device is an electronic atomizing device.

[0030] The beneficial effects of this invention are:

[0031] The present invention provides a nicotine-simulating composition comprising a first composition and a second composition; the first composition comprises lactamide; and the second composition comprises piperine. The specific first composition of the present invention can produce a nicotine-like effect in the brain, and the specific second composition can produce a nicotine-like throat hit. Through the synergistic effect of the specific first and second compositions, the user's satisfaction can be significantly enhanced. Therefore, the present invention selects the specific first and second compositions as a nicotine-simulating composition, and through their synergistic effect, enhances the satisfaction of zero-nicotine liquid formulations or low-concentration nicotine liquid formulations, thereby achieving the user's physiological craving relief. Detailed Implementation

[0032] The following embodiments are provided to better understand the present invention and are not limited to the preferred embodiments described. They do not constitute a limitation on the content and scope of protection of the present invention. Any product that is the same as or similar to the present invention, derived by any person under the guidance of the present invention or by combining the features of the present invention with other prior art, falls within the protection scope of the present invention.

[0033] For experiments not specifically described in the examples, the procedures or conditions should be followed according to the conventional experimental procedures described in the literature in this field. Reagents or instruments whose manufacturers are not specified are all commercially available conventional reagent products.

[0034] Electronic atomizing devices mainly consist of a battery, an atomizer, nicotine liquid, and a mouthpiece. The battery provides power to the atomizer, which heats the nicotine liquid and atomizes it into tiny particles, forming an aerosol. Consumers inhale these aerosols through the mouthpiece, thus obtaining an experience similar to smoking. Based on nicotine content, electronic atomizing devices can be divided into nicotine-containing and nicotine-free categories. Nicotine-containing electronic atomizing devices satisfy the smoker's physiological needs through nicotine release, while nicotine-free electronic atomizing devices primarily rely on other ingredients to provide taste and satisfaction. With increasing public awareness of health, many countries have strengthened their regulations on e-cigarettes. Nicotine-containing electronic atomizing devices are limited to a nicotine content of no more than 20mg / g, and many countries are promoting nicotine-free electronic atomizing devices.

[0035] Nicotine is addictive and a primary substance in the formation of nicotine addiction. Therefore, for many smokers, it is crucial that low-nicotine or zero-nicotine products can satisfy their physiological cravings and achieve a high level of satisfaction without posing excessive health risks. Currently, low-nicotine and zero-nicotine products mainly attract consumers with their rich flavors and cool, refreshing sensation. To address the lack of satisfaction, some researchers have tried adding natural alkaloids from traditional Chinese medicine to enhance the product's satisfaction. However, this method can affect the product's aroma and flavor, reducing its overall taste quality, and has limited effect on improving satisfaction.

[0036] Therefore, the present invention provides a nicotine-simulating composition comprising a first composition and a second composition; the first composition comprising lactamide; and the second composition comprising piperine.

[0037] Lactic acid is an organic compound. The inventors used molecular docking technology to discover that its target is neuronal nicotinic acetylcholine receptors (nAChRs), and its mechanism of action and efficacy are similar to nicotine.

[0038] Piperine is an alkaloid, the source of the spiciness of pepper, and its most important bioactive component. Piperine is a regulator of human transient receptor potential (TRP) channels. The oral cavity and throat contain various TRP channels, such as the transient receptor potential ankylosing spiciness channel (TRPA1) and the transient receptor potential vanillin 1 (TRPV1) channel. Activation of the TRPA1 channel primarily produces a pain sensation. Piperine can also activate human TRPA1 channels, thus causing sensations in the throat such as pain, irritation, and tingling. This is similar to nicotine, which also activates TRP channels, creating the throat hit sensation. Furthermore, the inventors discovered that piperine also inhibits enzymes that play important roles in drug metabolism. By inhibiting drug metabolism, piperine may be able to improve the bioavailability of many compounds, thereby enhancing the bioactivity of alkaloids in the human body and helping to increase the "pungency" (the physiological satisfaction derived from nicotine or similar substances in cigarette smoke).

[0039] The inventors discovered that by adapting piperine, they could simulate the throat hit sensation of nicotine, enhance the throat hit sensation of low-concentration nicotine and zero-nicotine products, and increase the perceived potency.

[0040] The inventors unexpectedly discovered that by specifically selecting lactamide as the first composition, a similar effect to nicotine's kick can be produced, and by specifically selecting piperine as the second composition, a similar effect to nicotine's throat hit can be produced. The two compositions, working synergistically, can significantly enhance the user's satisfaction with zero-nicotine or low-nicotine liquid formulations (referring to the overall experience of the kick, throat hit, and aroma saturation after the liquid formulation is atomized), thereby achieving the user's physiological craving relief.

[0041] In some alternative embodiments, the mass ratio of the first composition to the second composition is (1-30):(0.05-5). For example, the mass ratio of the first composition and the second composition can be optionally 1:0.05, 1:0.07, 1:0.09, 1:0.1, 1:0.2, 3:4.5, 3:4.8, 3:5, 5:0.05, 5:0.07, 5:0.09, 5:0.1, 5:0.2, 5:0.3, 5:0.4, 5:0.5, 5:1, 5:1.2, 5:1.5, 5:1.8, 5:2, 5:2.8, 5:3, 5:4, 5:4.8, 5:5, 10:0.05, 10:0.07, 10:0.09, 10:0.1, 10:0.2, 10:0.3, 10:0.4, 10:0.5, 10:1, or 10:1.2. 10:1.5, 15:5, 21:0.05, 21:0.07, 21:0.09, 21:0.5, 21:1, 21:1.2, 21:1.5, 21:1.8, 21:2, 21:2.5, 21:2.8, 21:3, 21:3.2, 21:3.5, 21:3.8, 21:4, 21: 4.2, 21:4.5, 21:4.8, 21:5, 25:0.05, 25:0.07, 30:0.2, 30:0.3, 30:0.4, 30:0.5, 30:1, 30:2.8, 30:3, 30:3.2, 30:3.5, 30:3.8, 30:4, 30:4.2, 30:4.5.

[0042] In some alternative embodiments, the first composition further includes magnolol.

[0043] Magnolol is the main active ingredient in Magnolia officinalis extract. Magnolia officinalis is a traditional Chinese medicine with diverse pharmacological activities and a wide range of pharmacological effects, such as antidepressant effects, regulation of monoamine neurotransmitter activity, anti-inflammation, and neuroprotection. The inventors discovered that magnoolol can increase the levels of serotonin and dopamine in the frontal cortex of mice.

[0044] The inventors unexpectedly discovered that combining lactamide and magnolol could produce a nicotine-like kick and, synergistically, further enhance the satisfaction of low-concentration or zero-nicotine products.

[0045] In some optional embodiments, the mass ratio of lactamide to magnolol is (1-15):(1-15). For example, the mass ratio of lactamide to magnolol can be selected as 1:15, 6:15, 10:15, 11:15, 13:15, 6:14, 10:14, 2:13, 11:13, 15:13, 1:12, 2:12, 8:11:12, 13:12, 1:11, 2:11, 4:11, 8:11, 9:11, 15:11, 1:10, 2:10, 13:10, 14:10, 1:9, 2:11:9, 12:9, 14:9, 15:9, 2:8. 4:8, 5:8, 6:8, 12:8, 13:8, 15:8, 1:7, 5:7, 10:7, 11:7, 12:7, 9:6, 12:6, 13:6, 14:6, 15:6, 14:5, 15:5, 10:4, 14:4, 15:4, 10:3, 13:3, 14:3, 15:3, 1:2, 2:2, 3:2, 9:2, 13:2, 14:2, 2:1, 3:1, 4:1, 8:1, 9:1, 10:1, 13:1, 14:1, 15:1.

[0046] In some optional embodiments, the first composition is lactamide and magnolol, and the second composition is piperine; optionally, the mass ratio of lactamide, magnolol and piperine is (1-15):(1-15):(0.01-0.5). For example, the mass ratios of lactamide, magnolol, and piperine can be selected as 5:5:0.05, 5:5:0.5, 10:5:0.05, 10:5:0.5, 15:5:0.05, 15:5:0.5, 5:10:0.05, 5:10:0.5, 10:10:0.05, 10:10:0.5, 15:10:0.05, 15:10:0.5, 5:15:0.05, 5:15:0.5, 10:15:0.05, 10:15:0.5, 15:15:0.05, 15:15:0.5. This invention specifically utilizes the synergistic effect of lactamide, magnolol, and piperine in a zero-nicotine liquid formulation to achieve a level of satisfaction that essentially matches or even surpasses that of commercially available nicotine liquid formulations with a nicotine content of 10 mg / g.

[0047] This invention provides a liquid formulation whose raw material components include an atomizing solvent and the aforementioned nicotine-simulating composition. The inventors have discovered that the liquid formulation, including the aforementioned nicotine-simulating composition, can significantly enhance the user's satisfaction with the liquid formulation through its synergistic effect, thereby achieving the user's physiological craving relief.

[0048] In some optional embodiments, the mass concentration of the simulated nicotine composition in the liquid formulation is 0.5%-30.5%. For example, the mass concentration of the simulated nicotine composition in the liquid formulation can be selected as 0.5%, 0.7%, 1%, 2%, 2.8%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 16.5%, 17%, 18%, 19%, 20%, 21%, 21.5%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, or 30.5%. Preferably, when the mass concentration of the simulated nicotine composition in the liquid formulation is 0.5-16%, the aroma reproduction and aroma harmony of the liquid formulation are significantly unaffected.

[0049] In some optional embodiments, the mass concentration of the first composition in the liquid formulation is 0.5%-30%. For example, the mass concentration of the first composition in the liquid formulation may be selected as 1%, 3%, 5%, 10%, 15%, 20%, 25%, 27%, or 30%.

[0050] In some optional embodiments, the mass concentration of the second composition in the liquid formulation is 0.0005%-0.5%. For example, the mass concentration of the second composition in the liquid formulation may be selected as 0.0005%, 0.001%, 0.005%, 0.008%, 0.01%, 0.05%, 0.08%, 0.1%, 0.2%, 0.3%, 0.4%, or 0.5%.

[0051] In some optional embodiments, the atomizing solvent may be a conventional atomizing solvent in the art, including but not limited to propylene glycol and glycerol. Optionally, the mass concentration of the atomizing solvent in the liquid formulation is 40%-90%; for example, the mass concentration of the atomizing solvent in the liquid formulation may be 40%, 42%, 45%, 48%, 50%, 55%, 53%, 57%, 60%, 62%, 65%, 67%, 70%, 72%, 75%, 78%, 80%, 82%, 85%, 88%, or 90%. Optionally, the atomizing solvent includes at least one of propylene glycol and glycerol; preferably, the atomizing solvent is propylene glycol and glycerol; the mass ratio of propylene glycol to glycerol is (1-10):(1-10). For example, the mass ratio of propylene glycol to glycerol can be selected as 1:1, 1:3, 1:5, 1:7, 1:9, 1:10, 2:1, 2:3, 2:5, 2:3, 3:1, 3:2, 4:1, 4:3, 5:1, 5:2, 5:3, 5:4, 6:1, 6:5, 7:1, 7:2, 7:3, 7:4, 7:5, 7:6, 8:1, 8:3, 8:5, 8:7, 9:1, 9:2, 9:4, 9:5, 9:7, 9:8, 10:1, 10:3, 10:4, 10:5, 10:6, 10:7, 10:8, or 10:9. The addition of the atomizing solvent in this invention can better dissolve the raw material components, effectively improve the atomization efficiency of nicotine, and increase satisfaction.

[0052] In some optional embodiments, the raw material components of the liquid formulation further include a flavoring. The flavoring can be a conventional, existing flavoring material in the art, such as a single flavoring ingredient or a mixture of extracts, or commercially available. This includes, but is not limited to, tobacco flavorings, fruit flavorings, compound tobacco flavorings, and mint flavorings. Optionally, the flavoring includes at least one of strawberry flavoring, mint flavoring, and mango flavoring. Optionally, the mass ratio of the simulated nicotine composition to the flavoring is (0.05-30.5):(20-400). For example, the mass ratio of the simulated nicotine composition to the flavoring can be selected as follows: 0.05:20, 0.05:30, 0.05:40, 0.5:20, 0.5:30, 0.5:40, 1.05:20, 1.05:30, 1.05:40, 5:20, 5:30, 5:40, 7:20, 7:30, 7:40, 10:20, 10:30, 10:40, 15:20, 15:30, 15:40, 20:20, 20:30, 20:40, 25:20, 25:30, 25:40, 30:20, 30:30, 30:40, 30.5:20, 30.5:30, 30 0.5:40, 0.05:200, 0.05:300, 0.05:400, 0.5:200, 0.5:300, 0.5:400, 1.05:200, 1.05:300, 1.05:400, 5:200, 5:30, 5:400, 10:200, 10:300, 10:400, 15:200, 15:300, 15:400, 20:200, 20:300, 20:400, 25:200, 25:300, 25:400, 30:200, 30:300, 30:400, 30.5:200, 30.5:300, 30.5:400.

[0053] In some optional embodiments, the liquid formulation comprises lactamide, magnolol, piperine, flavoring, propylene glycol, and glycerol. Optionally, the mass ratio of lactamide, magnolol, piperine, flavoring, propylene glycol, and glycerol is (1-15):(1-15):(0.01-0.5):(20-400):(10-900):(10-900).

[0054] This invention provides a method for preparing the above-described liquid formulation, comprising the following steps:

[0055] The nicotine-simulated composition is obtained by mixing it with an atomizing solvent and then heating and stirring until homogeneous.

[0056] In some optional embodiments, the method for preparing the liquid formulation further includes a step of adding flavoring before the heating and stirring step.

[0057] This invention does not specifically limit the heating and stirring temperature and time, as long as the raw materials can be dissolved. Optionally, the dissolution temperature should not exceed 100℃. Optionally, the heating and stirring temperature is 40-65℃, and the heating and stirring time is 20-30 minutes. This invention does not specifically limit the mixing method or the mixing order. Optionally, in this invention, all raw materials can be mixed and then heated to dissolve, or some raw materials can be mixed and dissolved first, and then the remaining raw materials can be mixed and dissolved.

[0058] In some optional embodiments, the method for preparing the nicotine liquid formulation includes the following steps: mixing a simulated nicotine composition and a portion of the atomizing solvent, heating at 40-65°C for 20-30 minutes to dissolve and mix evenly, then adding the fragrance and the remaining portion of the atomizing solvent, stirring at 10-50°C for 5-40 minutes to mix evenly, to obtain the liquid formulation.

[0059] The present invention also provides the application of the above-described nicotine-simulated composition, the above-described liquid formulation, or the liquid formulation prepared by the above-described preparation method in an atomizing device.

[0060] In some alternative implementations, the atomizing device is an electronic atomizing device.

[0061] The present invention will be further described in detail below with reference to specific embodiments, which should not be construed as limiting the scope of protection claimed by the present invention.

[0062] Example 1

[0063] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0064] Mix 0.5g lactamide, 0.005g piperine, and 19.495g propylene glycol, and stir at 60°C for 20 minutes to ensure uniform mixing. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to ensure uniform mixing, thus obtaining the liquid formulation.

[0065] Example 2

[0066] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0067] Mix 0.5g lactamide, 0.5g honokiol, 0.005g piperine and 18.995g propylene glycol, and stir at 60°C for 20 minutes to mix evenly. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to mix evenly to obtain the liquid preparation.

[0068] Example 3

[0069] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0070] Mix 1g lactamide, 0.5g honokiol, 0.01g piperine and 18.49g propylene glycol, and stir at 60°C for 20 minutes to mix evenly. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to mix evenly to obtain the liquid preparation.

[0071] Example 4

[0072] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0073] Mix 1g lactamide, 1g honokiol, 0.005g piperine and 17.995g propylene glycol, and stir at 60°C for 20 minutes to mix evenly. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to mix evenly to obtain the liquid preparation.

[0074] Example 5

[0075] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0076] Mix 1.5g lactamide, 1g honokiol, 0.005g piperine and 17.495g propylene glycol, and stir at 60°C for 20 minutes to mix evenly. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to mix evenly to obtain the liquid preparation.

[0077] Example 6

[0078] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0079] Mix 1.5g lactamide, 1.5g honokiol, 0.01g piperine and 16.99g propylene glycol, and stir at 60°C for 20 minutes to mix evenly. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to mix evenly to obtain the liquid preparation.

[0080] Example 7

[0081] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0082] Mix 1.5g lactamide, 1g honokiol, 0.05g piperine and 17.45g propylene glycol, and stir at 60°C for 20 minutes to mix evenly. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to mix evenly to obtain the liquid preparation.

[0083] Example 8

[0084] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0085] Mix 1.5g lactamide, 1.5g honokiol, 0.05g piperine and 16.95g propylene glycol, and stir at 60°C for 20 minutes to mix evenly. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to mix evenly to obtain the liquid preparation.

[0086] Example 9

[0087] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0088] Mix 1.5g lactamide, 0.01g piperine, and 18.49g propylene glycol, and stir at 60°C for 20 minutes to ensure uniform mixing. Then add 40g mango flavoring and 40g glycerol, and stir at room temperature for 20 minutes to ensure uniform mixing, thus obtaining the liquid formulation.

[0089] Comparative Example 1

[0090] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0091] Mix 40g of mango flavoring, 20g of glycerol, and 40g of glycerol at room temperature for 20 minutes to obtain the liquid preparation.

[0092] Comparative Example 2

[0093] This comparative example provides a method for preparing a nicotine liquid formulation, comprising the following steps:

[0094] Dissolve 1g of nicotine and 0.75g of benzoic acid in 18.25g of propylene glycol, heat at 50°C for 20 minutes to mix evenly, then add 40g of mango flavoring and 40g of glycerol, stir at room temperature for 20 minutes to mix evenly, to obtain the nicotine liquid preparation.

[0095] Comparative Example 3

[0096] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0097] Mix 1.5g magnolol, 0.01g piperine and 18.49g propylene glycol, stir at 60°C for 20 minutes to mix evenly, then add 40g mango flavoring and 40g glycerol, stir at room temperature for 20 minutes to mix evenly, to obtain the liquid preparation.

[0098] Comparative Example 4

[0099] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0100] Mix 1g lactamide, 0.51g honokiol and 18.49g propylene glycol, stir at 60°C for 20 minutes to mix evenly, then add 40g mango flavoring and 40g glycerol, stir at room temperature for 20 minutes to mix evenly, to obtain the liquid formulation.

[0101] Test case

[0102] This invention employs a subjective tasting method to score various tasting indicators for Examples 1-9 and Comparative Examples 1-4. The tasting team consists of 15 people, all of whom have more than 3 years of experience using traditional cigarettes and / or nicotine e-vaporization devices, and all of whom underwent nicotine withdrawal for 10 hours prior to the experiment.

[0103] Each participant received a quality evaluation form. A blind tasting method was used to evaluate the compound e-liquids. The tasting method was as follows: participants fasted from nicotine the night before tasting and conducted the test at 9:00 AM on the day of tasting. Using an e-cigarette (with different examples and comparative samples), participants took 10 puffs (3 seconds per puff, with a 27-second interval between puffs). After each puff, participants scored the e-liquids according to the evaluation indicators in Table 1, ranging from 0 to 10. After tasting one sample e-liquid, participants fasted for 2 hours before testing the next sample. The test results are shown in Table 2 (scores are average scores).

[0104] Table 1 Evaluation Indicators

[0105]

[0106] Table 2. Smoking Scoring Data

[0107] sample energy Throat hit satisfaction Aroma saturation Aroma fidelity Aroma Harmony Cooling sensation Example 1 1.87 3.13 2.60 6.20 7.33 7.67 2.27 Example 2 2.20 3.07 2.87 6.13 7.60 7.53 2.00 Example 3 2.53 3.53 3.20 5.93 7.53 7.27 2.13 Example 4 3.20 2.93 3.07 6.00 7.07 6.80 2.07 Example 5 3.60 3.07 3.47 6.60 7.07 6.33 2.07 Example 6 4.20 3.67 4.13 6.53 7.12 6.27 2.00 Example 7 3.93 4.20 3.50 6.07 7.20 6.33 1.93 Example 8 4.40 4.13 3.53 6.13 6.80 5.87 2.07 Example 9 1.73 3.60 2.87 6.13 7.80 7.60 2.80 Comparative Example 1 0 0 0 6.12 7.31 7.6 2.17 Comparative Example 2 3.53 3.13 3.47 6.27 7.40 7.33 2.00 Comparative Example 3 1.67 3.53 2.40 5.53 7.33 7.80 2.60 Comparative Example 4 2.67 0.20 2.52 5.73 7.20 7.67 2.27

[0108] The subjective tasting results in Table 2 show that different combinations of boosting and throat-hitting agents produce varying degrees of satisfaction. Examples 1-4 demonstrate stronger levels of satisfaction than Comparative Example 1 in terms of boost, throat hit, and overall satisfaction; indicating that the standard nicotine-free liquid formulation of Comparative Example 1 lacks boost, throat hit, and satisfaction. However, the combination of lactamide and piperine, as well as the combination of lactamide, magnolol, and piperine in a standard nicotine-free formulation, exhibits enhanced satisfaction.

[0109] Examples 5-8 and Comparative Example 2: Example 5 achieved the same level of strength, throat hit, and overall satisfaction as Comparative Example 2. Examples 6-8: Increasing the concentrations of lactamide, magnolol, and piperine improved the strength and throat hit, but did not significantly improve overall satisfaction. This was mainly because increasing the piperine content increased the throat irritation, negatively impacting the vaping experience and leading to a decrease in satisfaction. This indicates that there is an optimal concentration of piperine for enhancing satisfaction. Example 6 achieved slightly higher satisfaction than Comparative Example 2; however, increasing the content of lactamide and magnolol affected the aroma. Therefore, higher amounts of these two substances are not always better, as they can negatively impact the vaping experience. Adjusting the amounts of these substances is necessary to balance the aroma and satisfaction experience.

[0110] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.

Claims

1. A nicotine-simulating composition, characterized in that, The simulated nicotine composition comprises a first composition and a second composition; The first composition includes lactamide; The second composition includes piperine.

2. The nicotine-simulated composition according to claim 1, characterized in that, The mass ratio of the first composition to the second composition is (1-30):(0.05-0.5).

3. The nicotine-simulated composition according to claim 1 or 2, characterized in that, The first composition also includes magnolol.

4. The nicotine-simulated composition according to claim 3, characterized in that, The mass ratio of lactamide to magnolol is (1-15):(1-15).

5. The nicotine-simulated composition according to any one of claims 1-4, characterized in that, The first composition is lactamide and magnolol, and the second composition is piperine; Optionally, the mass ratio of lactamide, magnolol and piperine is (1-15):(1-15):(0.01-0.5).

6. A liquid formulation, characterized in that, The raw material components of the liquid formulation include an atomizing solvent and the nicotine-simulated composition according to any one of claims 1-5.

7. The liquid formulation according to claim 6, characterized in that, The mass concentration of the simulated nicotine composition in the liquid formulation is 0.5%-30.5%.

8. The liquid formulation according to claim 6 or 7, characterized in that, The mass concentration of the first composition in the liquid formulation is 0.5%-30%; And / or, the mass concentration of the second composition in the liquid formulation is 0.0005%-0.5%.

9. The liquid formulation according to any one of claims 6-8, characterized in that, The atomizing solvent includes at least one of propylene glycol and glycerol.

10. The liquid formulation according to any one of claims 6-9, characterized in that, The atomizing solvent is propylene glycol and glycerol; Optionally, the mass ratio of propylene glycol to glycerol is (1-10):(1-10).

11. The liquid formulation according to any one of claims 6-10, characterized in that, The raw material components of the liquid preparation also include flavorings.

12. The liquid formulation according to claim 11, characterized in that, The flavoring includes at least one of strawberry flavoring, mint flavoring, and mango flavoring.

13. The liquid formulation according to claim 11 or 12, characterized in that, The mass ratio of the simulated nicotine composition to the fragrance is (0.05-30.5):(20-400).

14. A method for preparing a liquid formulation according to any one of claims 6-13, characterized in that, Includes the following steps: The nicotine-simulated composition is obtained by mixing it with an atomizing solvent and then heating and stirring until homogeneous.

15. The method for preparing the liquid formulation according to claim 14, characterized in that, It also includes the step of adding flavoring.

16. The use of the nicotine-simulated composition according to any one of claims 1-5, the liquid formulation according to any one of claims 6-15, or the liquid formulation prepared by the preparation method according to claims 14 or 16 in an atomizing device.

17. The application according to claim 16, characterized in that, The atomizing device is an electronic atomizing device.

Images